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Quality of Life in Taiwanese Breast Cancer Survivors
With Breast-conserving Therapy
Chi-Cheng Huang,1,2,3 Heng-Hui Lien,2,4 Shih-Hsin Tu,4 Ching-Shui Huang,4 Jaan-Yeh Jeng,1
Hui-Lin Chao,5 Hsiao-Lun Sun,2,6 Wei-Chu Chie7*
Background/Purpose: Breast cancer is the most common female malignancy in Taiwan; however, quality
of life (QOL) following breast cancer therapy remains rarely studied. The aim of the present study was to
evaluate QOL among Taiwanese breast cancer patients with and without breast-conserving therapy.
Methods: A total of 130 women with breast cancer (37 with breast-conserving therapy and 93 with mod-
ified radical mastectomy) were enrolled between August, 2004 and December, 2007 in a single center.
Patients who underwent breast-conserving therapy were younger, less likely to be married, had a higher
educational level, and were at an earlier clinical stage than those who underwent modified radical mastec-
tomy. The traditional Chinese version of the European Organization for Research and Treatment of Cancer
QLQ-C30 and QLQ-BR23 questionnaires were used as measuring instruments. Structural equation mod-
eling with mean structural analysis, which evaluates configuration invariance and compares groups for 
latent functional/symptomatic factors, was constructed using a multi-indicators approach.
Results: Patients with breast-conserving therapy reported worse global QOL status and role function
scores and higher symptomatic scores for fatigue, pain, dyspnea, insomnia, appetite loss, breast and arm
problem subscales than those without conserving therapy. In addition, age, marital status, hormone 
manipulation and postoperative adjuvant therapy were significant confounders for QOL. Measurement
invariance was ascertained and the same QOL construct could be applied to Taiwanese subjects with and
without breast-conserving therapy.
Conclusion: Our study suggests that breast-conserving therapy might be associated with worse perceived
QOL for Taiwanese breast cancer survivors.
Key Words: breast-conserving therapy, EORTC QLQ-BR23, EORTC QLQ-C30, quality of life, structural
equation modeling
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Breast cancer is the leading cause of female ma-
lignancy in Taiwan according to the 2003 Taiwan
Cancer Registry Annual Report;1 5325 incident
cases were diagnosed, and this number was roughly
one-fifth of all female malignancies. Evidence has
accumulated about psychosocial consequences of
breast cancer therapy, and quality of life (QOL)
is regarded as one of the clinical outcomes.2–7
Breast-conserving therapy (partial mastectomy
with postoperative irradiation) has been advo-
cated as an alternative to the standard procedure
of modified radical mastectomy, for comparable
long-term clinical outcomes and cosmetic consid-
eration.8,9 However, most Taiwanese women with
breast cancer prefer modified radical mastectomy
rather than breast-conserving therapy, despite the
shortcoming of body image destruction. Compli-
cations and QOL status following breast surgery
have rarely been investigated in Taiwan. Most
postoperative breast cancer QOL studies have been
conducted among western women,10 but cross-
cultural differences might hinder applying the
conclusions to Taiwanese women. Furthermore, in
the limited number of surveys of QOL of breast
cancer patients in Taiwan, there is no information
on QOL after breast-conserving therapy because of
the low use of this treatment strategy, even though
it is designed to improve body image.11,12
The objective of this study was to evaluate the
effects of breast-conserving therapy on QOL of
Taiwanese women, with adjustment for other con-
founders. The approach was based on structure
equation modeling, with an emphasis on a means
model. Group means/intercepts on latent exoge-
nous/endogenous QOL factors were evaluated
accordingly. Our work represents the continuous
effort to apply structural equation modeling to
QOL research, with the highlight of latent func-
tional/symptomatic domain variables. Implicated
relationships between observed (questionnaire
items) and latent variables (functional/sympto-
matic domain subscales or higher-order factors)
were evaluated using confirmatory factor analysis
to generate a comprehensive and global specula-
tion of a health-related QOL construct. The impact
of breast-conserving therapy upon subjective QOL
perception by breast cancer survivors was eluci-
dated using structural modeling.
Patients and Methods
Study design
Study subjects were breast cancer patients who had
completed surgery and/or adjuvant therapy, if in-
dicated, and were undergoing regular follow-up.
All subjects must have completed surgery or their
final course of adjuvant therapy (except oral hor-
mone manipulation therapy) for at least 9 months
when QOL scores were measured. Outcomes were
health-related QOL scores. The whole study de-
sign was approved by the Institute Review Board
of the Cathay General Hospital. Eligible patients
were well informed of the objectives and confiden-
tiality policy of this study and informed consent
was obtained from all participants.
Study population
Between August, 2004 and December, 2007, 130
women with incidental breast cancers were diag-
nosed and treated in the Cathay General Hospital.
Patients presented with curable diseases (no dis-
tant metastasis) and were offered counseling for
the surgical options of breast-conserving therapy
or modified radical mastectomy. Table 1 summa-
rizes the demographic and clinical features of the
study population. Patients who chose breast-
conserving therapy rather than modified radical
mastectomy tended to be younger and single, and
to have a higher education level and earlier clinical
stage of cancer. There was no difference regarding
postoperative adjuvant therapy between these two
groups. Hormone manipulation therapy such as
tamoxifen or aromatase inhibitor was prescribed
less frequently for the breast-conserving therapy
group.
Measuring instruments
The European Organization for Research and Treat-
ment of Cancer (EORTC) QLQ-C30 and QLQ-
BR23 questionnaires were used to assess QOL 
of breast cancer patients. EORTC QLQ-C30 is a
C.C. Huang, et al
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generic QOL measuring instrument for cancer
patients. It comprises a global health status/QOL,
five multi-item functional subscales and several
single/multi-item symptomatic subscales. Four-
to-seven-level Likert scales (seven for global health
status/QOL and four for the others) are linearly
transformed to a 0–100 score, with higher scores
indicating better functional status or worse sym-
ptomatic problems.13 EORTC QLQ-BR23 is a 
23-item breast cancer site-specific supplemental
module for QLQ-C30 to enhance the sensitivity
and specificity for breast cancer QOL measures.
The original English version comprises five multi-
item subscales and three single-item subscales,
with higher scores for better functional or worse
symptomatic QOL conditions.14,15 The Taiwan
Chinese version of EORTC QLQ-C30 has been
validated for breast, lung, head and neck, and gas-
tric cancer,12,15–17 and that of EORTC QLQ-BR23
has been validated for breast cancer in Taiwan.12
The questionnaires were self-administered during
the predefined time frame, 9–12 months after
completion of surgery or postoperative adjuvant
therapy, at the scheduled follow-up visits.
Statistical analysis
The Wilcoxon rank sum test was used for univari-
ate between-group comparisons. A p value < 0.01
was considered statistically significant in each QOL
subscale. QOL scores with significant between-
group differences were further evaluated by mul-
tivariate regression to adjust for confounders. All
statistical analyses were conducted using SAS/
STAT version 9.1 with procedures, NPAR1WAY and
GLM (SAS Institute Inc., Cary, NC, USA).
QOL subscales, either functional or sympto-
matic, with scores predictable by breast-conserving
therapy, along with relevant confounders, were
selected for structural equation modeling. Func-
tional and symptomatic domains were evaluated
by EORTC QLQ-C30 and QLQ-BR23; therefore,
two latent variables, functional and symptomatic
status factors, were constructed and realized by
observable QOL subscale scores in functional and
symptomatic domains, respectively. The cause–
effect relationship between latent symptomatic
and functional factors was quantified by regression
weight. The rationale for such an arrangement
came from the hypothesis that worse symptoms
Table 1. Demographic and clinical features of study population*
Breast conserving therapy Modified radical mastectomy 
p†
(n = 37) (n = 93)
Age (yr) 51.1 (22–78) 55.1 (32–77) 0.04
Married 31 (83.8) 89 (95.7) 0.02
Education
High school 13 52 < 0.01
University 9 38
Graduate school 15 3
Stage
0 7 3 < 0.01
I 15 24
II 10 49
III 5 17
Adjuvant therapy 30 (81.1) 68 (73.1) 0.34
Chemotherapy only 6 55
Radiotherapy only 15 1
Chemo-radiotherapy 9 12
Hormone manipulation therapy 22 (59.5) 76 (81.7) < 0.01
*Data presented as median (range) or n (%); †c2 test for categorical and t test for continuous variables.
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might cause QOL function deterioration, as sug-
gested by Fayes et al in their causal-indicators
model.18,19 QOL scores and potential confound-
ers were treated as endogenous and exogenous
observed variables in this construct.
For structural equation modeling, goodness
of fit was evaluated by χ2 and the ratio of χ2 to
the degree of freedom. A ratio of < 3 indicated a
good fit of the hypothesized model to the exper-
imental data. Other fit indexes included: goodness
of fix index (GFI) > 0.90, adjusted GFI > 0.80; stan-
dardized root mean square residual (RMR) < 0.1;
comparative fit index (CFI) > 0.9; root mean
square error of approximation (RMSEA) < 0.08;
normed fix index (NFI) > 0.9; non-normed fix
index (NNFI) > 0.9; and incremental fix index
(IFI) > 0.9.20–25 Global model fitness of the struc-
tural equation modeling construct was tested and
indicated by absolute (χ2, GFI, adjusted GFI, stan-
dardized RMR, and RMSEA), incremental (NFI
and NNFI) and parsimonious (CFI and IFI) fit
measures.26 Statistical works with structural equa-
tion modeling were performed with AMOS ver-
sion 6.0 (SPSS Inc., Chicago, IL, USA).
Measurement invariance
Measurement invariance was guaranteed in two
steps. First, multi-group structural equation mod-
eling was performed and factor loadings for each
group were estimated separately. Configuration
or pattern invariance across groups was ascer-
tained and pair-wise comparisons of factor loading
of each QOL domain/subscale were performed.
Factorial invariance was claimed when factor
loadings for different groups were the same for
most QOL subscales. Second, after assuring fac-
tor and structure homogeneity across groups with
equal values, latent variables (intercepts for en-
dogenous and means for exogenous variables)
were allowed to be estimated separately for each
group, as were regression weights between latent
variables within each group. Generally, mean
structural analysis was based on the prerequisite
of structural equation modeling with equal fac-
tor loadings in most measurement domains for
all groups, but allowed latent variables to change
across groups in intercept/mean and distinct esti-
mation of regression weights for each group if mul-
tiple latent variables were included in the model.
Results
QOL in patients with and without 
breast-conserving therapy
Univariate analysis revealed that the breast-
conserving therapy group experienced worse global
health status/QOL and role function, as well as
more fatigue, pain, dyspnea, insomnia, appetite
loss, breast and arm symptoms, than the modified
radical mastectomy group. In general, patients with
breast-conserving therapy reported lower functional
domain QOL scores and worse (higher) sympto-
matic domain QOL scores. The only exception was
the sex enjoyment subscale of EORTC QLQ-BR23,
for which, more satisfaction was observed for the
breast-conserving therapy group (Table 2).
Multivariate analysis
Table 3 shows regression weights when multiple
linear regression analysis was performed with QOL
subscale scores as dependent variables. Breast-
conserving therapy inevitably exerted a negative
impact upon functional domain subscales and
worsened symptomatic domain subscales. When
Table 2. Mean quality of life score of study
population
Quality of 
Breast Modified 
life subscale
conserving radical 
therapy mastectomy
Global health status/QOL 56.3 68.1
Role function 73.9 89.7
Fatigue 37.2 22.5
Pain 34.7 15.4
Dyspnea 17.1 6.2
Insomnia 45.9 22.2
Appetite loss 21.6 8.1
Sex enjoyment 52.8 35.7
Breast symptoms 27.2 20.0
Arm symptoms 31.2 18.1
QOL = Quality of life.
Quality of life after breast-conserving therapy
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age was treated as a continuous variable, every
10-year gain in age was associated with a four-
point increase in dyspnea score. Marital status had
an adverse effect on role function and breast symp-
toms. Adjuvant therapy, as expected, caused dete-
rioration in insomnia, breast and arm symptoms.
Hormone manipulation therapy, however, showed
contradictory effects with worse insomnia but
fewer appetite loss problems. Neither education
level nor clinical staging was predictive of QOL.
It should be noted that sex enjoyment was no
longer predictable by breast-conserving therapy
after multivariate adjustment.
QOL construct with structural 
equation modeling
QOL subscales with significant differences in
scores between breast-conserving therapy and
modified radical mastectomy were treated as 
observed endogenous variables, and QOL con-
founders as observed exogenous variables. Two
latent variables, one for functional and the other
for symptomatic domains, were constructed and
the cause–effect relationship was expressed by
regression weight (symptomatic status factor
functional status factor, Figure). As a result of
missing values in some questionnaire items, there
were 117 subjects (35 in the breast-conserving
therapy group) available for structural equation
modeling analysis.
Multi-group model with mean/intercept fixed
to zero was tested first for measurement invari-
ance, and factor loadings for each group were es-
timated separately. Pair-wise comparisons revealed
between-group differences in factor loadings:
functional status factor role function, sympto-
matic status factorbreast symptoms, and regres-
sion weight: adjuvant therapybreast symptoms,
all of which had exceeded the critical ratio of 1.96
at an α level of 0.05. Point estimates of standard-
ized regression weights were: 0.820 versus 0.575
(functional status factor role function); 0.428
versus 0.709 (symptomatic status factorbreast
symptom); and 0.357 versus 0.102 (adjuvant
therapybreast symptom) for breast-conserving
therapy and modified radical mastectomy. Other
parameters showed no significant between-group
differences. A revised model with equal factor
loadings across groups (factorial invariance) was
constructed and model fitness parameters revealed
a significant χ2 difference of 28.505 (df = 15,
p = 0.015), which indicated a slightly compro-
mised model fit if measurement invariance was
assumed for the breast-conserving therapy and
modified radical mastectomy groups.
Based on factorial invariance assumption, a
means model with different means/intercepts
across groups was constructed. The mean of latent
exogenous symptomatic status factor, intercept
of latent endogenous functional status factor, and
Table 3. Regression weights of multiple linear regression analysis
Confounder
QOL subscale Breast conserving 
Age
Married Adjuvant Hormone manipulation 
therapy status therapy therapy
Global health status/QOL –9.7 – – – –
Role function –15.0 – –16.3 – –
Fatigue 13.3 – – – –
Pain 18.4 – – – –
Dyspnea 10.8 0.4 – – –
Insomnia 22.4 – – 12.1 12.0
Appetite loss 11.1 – – – –9.2
Sex enjoyment – – – – –
Breast symptoms 11.4 – 9.4 8.3 –
Arm symptoms 12.2 – – 11.5 –
QOL = Quality of life.
C.C. Huang, et al
498 J Formos Med Assoc | 2010 • Vol 109 • No 7
regression weight (symptomatic status factor
functional status factor) were estimated separately
for patients with and without breast-conserving
therapy. Regression weight (symptomatic status
factor functional status factor) was –1.127
(p < 0.001), which was compatible with a causal
relationship between these two latent variables,
and showed no difference between the breast-
conserving therapy and modified radical mastec-
tomy groups. The mean symptomatic status factor
for the breast-conserving therapy group was 15.917
higher than for the modified radical mastectomy
group, and was highly significant at the p < 0.001
level. The intercept of functional status factor was
4.425 higher for breast-conserving therapy but
was not statistically significant (p = 0.138).
Discussion
We conducted a cross-sectional QOL survey in
Taiwanese breast cancer patients who underwent
curative surgery with or without breast-conserving
therapy. For eastern countries where the incidence
of breast cancer is around half that in western
countries, the impact of relevant clinical factors
and demographic features upon QOL following
breast cancer surgery should be evaluated in-
dependently and thoroughly.1,10 We found that
patients who received breast-conserving therapy
rather than modified radical mastectomy reported
worse function and more symptoms, even after
adjusting for other confounders.
Many previous studies have emphasized the
benefits of functional preservation, and limited
breast resection, such as breast-conserving ther-
apy, might bring favorable cosmetic results and
subsequent better QOL, especially with regard to
body image, femininity, sexual function and other
dimensions.2–6 For example, Engel et al7 demon-
strated that breast-conserving therapy outperforms
modified radical mastectomy for better body
image, role and sex function scores in the EORTC
QLQ-C30 questionnaire. Optimistic outcomes for
Mar rf2
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Age
Adj
Hor
Hor
Mar
Adj
Adj
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dy
sl
ap
br
arm
fa
Fun Sym
–10.53
1.13
1.17
0.62
1.36
0.85
0.83
0.94
–1.13
0.34
9.20
6.67
–9.89
2.11
5.54
7.82
Figure. Quality of life construct with structural equation modeling. Two regression weights (funql2 and sym fa)
were set to unity as baseline. fun = Functional status factor; sym = symptomatic status factor; ql2 = global health
status/quality of life; rf2 = role function; fa = fatigue; pa = pain; dy = dyspnea; sl = insomnia; ap = appetite loss; br = breast
symptom; arm = arm symptom; mar = marital status; adj = adjuvant therapy; hor = hormone manipulation therapy.
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breast-conserving therapy using other measuring
tools have also been reported in the Asia–Pacific
region, such as India and Australia.27,28 Janz et al29
found that patients treated with breast-conserving
therapy experience subjectively better body image
than those treated with modified radical mastec-
tomy and reconstruction, whereas age and edu-
cation have been identified as QOL predictors. In
contrast, Shimozuma et al30 argued that there is
no association between type of surgery and QOL
1 year after breast cancer surgery.
Most QOL studies regarding postoperative
functional and symptomatic status have been per-
formed with standard and valid measuring instru-
ments, and have compared QOL scores between
groups with different treatment modalities or
other potential confounders. Usually, the same
study subjects have been tested several times for
each QOL subscale dimension. However, none has
investigated in depth the whole QOL construct,
including functional and symptomatic domains
simultaneously, and the correlation between these
two domains across multiple QOL subscales. To
overcome the problem of multiple tests in the
same study population, and to treat the QOL
construct as a whole with underlying factor/
pathway structure incorporated into model fit-
ness, structural equation modeling with multiple
indicators was performed and acted as the main
analytical strategy in the current study.
The advantages of structural equation model-
ing rather than direct QOL scores comparison 
include simultaneous parameter estimation and
serial model fitness evaluation. Relationships be-
tween the observed variables (QOL scores) and
latent variables (functional and symptomatic sta-
tus factors) are evaluated in a hierarchical manner.
Measurement and equation errors are estimated
separately. Structural equation modeling has been
adopted for generic instruments such as the Short
Form-36 (SF-36) Health Survey31,32 and cancer-
tailored EORTC questionnaires.33 The initial effort
of using structural equation modeling for EORTC
QLQ-C30 (version 1.0) was proposed by Fayers
et al,18 by separating the causal variables (symp-
toms) from the effect indicator variables (QOL
domains). In 2006, Boehmer et al34 expanded the
concept of causal and indicator variables to eval-
uate fully the multifactorial structure of QLQ-
C30, except items that measure global health
status/QOL (Q29 and Q30). They named the
causal-indicator variables approach the “multiple
indicator multiple cause” (MIMIC) method. In
the current study, the causal relationship between
symptomatology and QOL functionality was
quantified by regression weight, with the latter
regressed on the former.
For structural equation modeling with multiple
study populations, such as in the current study,
there are two levels of measurement invariance. The
first is configuration or pattern invariance, to guar-
antee that the factor/pathway structure remains the
same across multiple groups. The second is that
when factor loadings are equal across groups (fac-
torial invariance), underlying latent factor means
and intercepts are relaxed for estimation. As already
mentioned, mean/intercept estimation (structure
mean modeling) is based on the prerequisite that
factor loadings are equal across all groups to
guarantee the comparability of latent factors.
Initially non-parametric univariate analysis
revealed that role function, global health status/
QOL, sex enjoyment and problems such as fa-
tigue, pain, dyspnea, insomnia, appetite loss,
breast and arm symptoms were QOL subscales
that showed significant score differences between
breast-conserving therapy and modified radical
mastectomy patients. Other QOL confounders,
including age, education level, clinical stage, mar-
ital status, adjuvant therapy, and hormone ma-
nipulation therapy, were incorporated into linear
regression models, and their impacts upon QOL
were evaluated as regression weights in multiple
linear regression analysis. It should be noted that
our study did not have a randomized controlled
design. It was not easy to allocate subjects to dif-
ferent surgical modalities without bias, such as
personal preference, prior knowledge and value
judgment on breast-conserving therapy, financial
affordability, body image perception and other
factors. The choice of breast-conserving therapy
or traditional modified radical mastectomy is
C.C. Huang, et al
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complex, while some confounders are observable
and others might not be. However, we tried to
collect as many QOL confounders as possible to
reduce the bias to a minimum. Besides, only sig-
nificant QOL subscales were enrolled as depend-
ent variables in multiple linear regression and the
structural equation modeling construct. The vari-
ables selection strategy was to keep the model
parsimonious and avoid potential co-linearity
problems from highly correlated QOL data.
Adjuvant therapy aggravated insomnia, breast
and arm symptoms. This finding is in consistency
with previous studies.35–37 Hormone manipulation
therapy remained a conflicting QOL predictor
because it had both a positive and negative effect
on appetite loss and insomnia. In general, few side
effects are now widely acknowledged for hormone
therapy in terms of health-related QOL.38,39 A
positive impact of breast-conserving therapy on
sex enjoyment has been reported elsewhere.10,40,41
The impact of breast-conserving therapy upon sex
enjoyment, however, became insignificant after
multivariate adjustment and was abandoned from
structural equation modeling analysis.
QOL subscales with significant between-group
difference and relevant confounders were selected
from univariate analysis and multivariate analysis,
and entered for structural equation modeling. For
configuration/pattern invariability, the equal fac-
tor loadings assumption was tested by pair-wise
comparisons: three (functional status factor role
function, symptomatic status factorbreast symp-
tom, and adjuvant therapybreast symptom)
were violations of between-group factorial equal-
ity. Despite this and slightly compromised model
fitness indexes, measurement invariance was
grossly satisfied, and the mean structural model
with endogenous latent intercepts and exogenous
latent means that were allowed to vary across
groups was constructed. Regression weight (symp-
tomatic status factor functional status factor)
was –1.127 and remained constant for breast-
conserving therapy and modified radical mas-
tectomy. The causal and negative effect of
symptomatic status factor upon functional status
factor was self-evident here. The mean of latent
symptomatic status factor, in contrast, was 15.917
higher for breast-conserving therapy. The null hy-
pothesis of equal intercept of latent functional
status factor was not rejected, which meant that
underlying functional status level was the same for
breast-conserving therapy and modified radical
mastectomy, after expelling the effect of the exoge-
nous symptomatic status factor and its regres-
sion power.
Our study demonstrated that compromised
functional and worse symptomatic scores reported
by breast-conserving therapy patients were mainly
attributed to the much higher mean latent symp-
tomatic status factor. Breast-conserving therapy is
understood to have better cosmetic effects than
modified radical mastectomy, at the expense of
postoperative adjuvant radiotherapy and more
frequent follow-up to detect recurrence. After ad-
justing for multiple QOL confounders, we found
that the breast-conserving therapy group suffered
from a higher mean latent symptomatic status fac-
tor, which in turn, was manifest as higher QOL
scores in multiple symptomatic domain subscales.
Our study showed that clinical staging had
little impact upon QOL. Our data also indicated
that, early stage or late stage breast cancer, once
cured, might enjoy similar levels of QOL. The same
phenomenon has been observed for Taiwanese
gastric cancer patients.42 Subjective perception of
health-related QOL might not necessarily be in
accordance with relevant clinical factors, such as
clinical stage, which predict long-term survival.
In conclusion, we found that breast-conserving
therapy had a negative impact on some aspects
of patients’ subjective QOL and more preoperative
communications with patients about the bene-
fits and pitfalls of breast conserving therapy are
necessary.
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